Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis

NCT01693679 is registered in ClinicalTrials.gov with Shao-quan Zhang as lead sponsor.

NCT NCT01693679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01693679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis
Lead sponsor
Shao-quan Zhang
Phase
Phase 4
Overall status
Unknown status
Start date
September 30, 2012
Completion date
Not reported
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hbv-related liver cirrhosis